Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the Parkinson' s disease market
- Related reports
- Upcoming reports
MARKET DEFINITION
- Market definition for this report
MARKET OVERVIEW
- Seven major markets
- Current and future market overview
- Opportunities and threats
- US
- Current and future market assessment
- Opportunities and threats
- Japan
- Current and future market assessment
- Opportunities and threats
- Five major European markets (5EU)
- Current and future market assessment
- Opportunities and threats
- France
- Current and future market assessment
- Germany
- Current and future market assessment
- Italy
- Current and future market assessment
- Spain
- Current and future market assessment
- UK
- Current and future market assessment
- Rest of the world snapshot
- Current market assessment
BRAND DYNAMICS
- Overview of competitive landscape
- Patient acquisition process
- Introduction
- Patient care path
- Points of influence in the patient care path
- Drivers of brand choice
- Ability to control motor symptoms
- Cost
- Side-effect profile
- Patient convenience
- Potential neuroprotective properties
- US formulary tier status for leading brands
- Mirapex and pramipexole ER (pramipexole, Boehringer Ingelheim)
- Drug overview
- Drug profile
- Product positioning
- Development of pramipexole extended-release
- SWOT analysis
- Brand forecast to 2018
- Requip and Requip XL (ropinirole extended-release; GlaxoSmithKline)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Neupro (rotigotine CDS, UCB)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Azilect (rasagiline, Teva/Lundbeck)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Comtan (entacapone, Novartis/Orion)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Stalevo (entacapone/carbidopa/levodopa, Novartis/Orion)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Duodopa (carbidopa, levodopa intestinal gel, Solvay)
- Drug overview
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Other dopamergic brands - levodopa and decarboxylase inhibitors
- Other dopamergic brand profiles
- Levodopa and decarboxylase inhibitor product positioning
- Brand forecast to 2018
- Safinamide (NW-1015, Merck Serono and Newron, Phase III)
- Drug overview
- Drug profile
- Development overview
- Product positioning
- Drug forecast to 2018
KEY DEVELOPERS
- Strategic overview
- Trends in corporate strategy
- Recent strategic partnerships/deals
- Boehringer Ingelheim
- Corporate strategy
- Parkinson' s disease portfolio assessment
- Novartis
- Corporate strategy
- Parkinson' s disease portfolio assessment
- UCB
- Corporate strategy
- Parkinson' s disease portfolio assessment
CASE STUDIES
- Introduction
- Dopaminergic drug delivery strategies in advanced Parkinson' s disease
- Large population which is inadequately controlled
- Add-on therapy is growing in advanced Parkinson' s disease market
- Current dopaminergic drug delivery approaches in advanced Parkinson' s
disease
- Pipeline dopaminergic drug delivery approaches in advanced Parkinson' s
disease
- Competition for companies targeting dopaminergic drug delivery
approaches in advanced Parkinson' s disease
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX A - MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Japanese market data
- Rest of World
- Derivation of sales forecasts and pricing trends
- Forecast methodology
APPENDIX B
- Contributing experts
- Conferences attended
- Report methodology
TABLES
- Table: Sales and growth of drug classes for Parkinson' s diseases in the
seven major markets, 2008 - 2018
- Table: Sales forecasts in Parkinson' s disease in the seven major markets
($m), 2008 - 2018
- Table: Summary of opportunities and threats in the Parkinson' s disease
market across the seven major pharmaceutical markets, 2009 - 2018
- Table: Prevalence of psychotic symptoms or hallucinations in Parkinson' s
disease
- Table: Sales and growth of drug classes for Parkinson' s diseases in the
US, 2008 - 2018
- Table: Sales forecasts in Parkinson' s disease in the US ($m), 2008 - 2018
- Table: Summary of opportunities and threats in the Parkinson' s disease
market in the US, 2009 - 2018
- Table: Sales and growth of drug classes for Parkinson' s diseases in Japan,
2008 - 2018
- Table: Sales forecasts in Parkinson' s disease in Japan ($m), 2008 - 2018
- Table: Summary of opportunities and threats in the Parkinson' s disease
market in Japan, 2009 - 2018
- Table: Sales and growth of drug classes for Parkinson' s diseases in the
5EU, 2008 - 2018
- Table: Sales forecasts in Parkinson' s disease across the 5EU ($m), 2008 -
2018
- Table: Summary of opportunities and threats in the Parkinson' s disease
market in the 5EU, 2009
- Table: Sales and growth of drug classes for Parkinson' s diseases in
France, 2008 - 2018
- Table: Sales and growth of drug classes for Parkinson' s diseases in
Germany, 2008 - 2018
- Table: Sales and growth of drug classes for Parkinson' s diseases in Italy,
2008 - 2018
- Table: Sales and growth of drug classes for Parkinson' s diseases in Spain,
2008 - 2018
- Table: Sales and growth of drug classes for Parkinson' s diseases in the
UK, 2008 - 2018
- Table: Global Parkinson' s disease-specific sales by region ($m), 2005 - 08
- Table: Leading branded drug sales for Parkinson' s disease in the seven
major markets ($m), 2008 - 2018
- Table: Representative formulary tier status in the US for leading brands
in Parkinson' s disease, 2009
- Table: Mirapex - Drug profile, 2009
- Table: Clinical trial summary for pramipexole extended-release
- Table: Key impacting factors on the revenues of Mirapex and pramipexole
extended-release, 2009 - 2018
- Table: Requip XL - Drug profile, 2009
- Table: Key impacting factors on the revenues of Requip and Requip
extended-release, 2009 - 2018
- Table: Neupro - Drug profile, 2009
- Table: Key impacting factors on the revenues of Neupro, 2009 - 2018
- Table: Azilect - Drug profile, 2009
- Table: Key impacting factors on the revenues of Azilect, 2009 - 2018
- Table: Comtan - Drug profile, 2009
- Table: Key impacting factors on the revenues of Comtan, 2009 - 2018
- Table: Stalevo - Drug profile, 2009
- Table: Key impacting factors on the revenues of Stalevo, 2009 - 2018
- Table: Duodopa - Drug profile, 2009
- Table: Key impacting factors on the revenues of Duodopa, 2009 - 2018
- Table: Dopamergic drug profiles, 2009
- Table: Safinamide - Drug profile, 2009
- Table: Clinical trial summary for safinamide, 2009
- Table: Key impacting factors on the revenues of safinamide, 2009 - 2018
- Table: Top 10 global N4A0 Anti-Parkinson ATC (Anatomical Therapeutic
Chemical) class market players, 2008
- Table: Key strategic deals in the Parkinson' s disease market, 2008 - 09
- Table: Global sales for Boehringer Ingelheim' s N4A0 Anti-Parkinson ATC
class drugs ($m), 2008
- Table: Global sales for Novartis' s 10 leading N4A0 Anti-Parkinson ATC
class drugs ($m), 2008
- Table: Prevalence of advanced Parkinson' s disease across the seven major
markets, 2009
- Table: Phase II gene therapies in development for Parkinson' s disease, 2009
- Table: Datamonitor' s launch dates for Parkinson' s disease products across
the seven major markets, 2008 - 2017
- Table: Patent expiry dates or generic launch dates for the approved
Parkinson' s disease brands in the 7MM, 2007 - 2017
FIGURES
- Figure: Parkinson' s disease-specific sales by country in the seven major
markets, 2005 - 2018
- Figure: Growth and market share amongst the seven major markets, 2005 - 08
- Figure: Parkinson' s disease-specific sales by class in the seven major
markets, 2005 - 2018
- Figure: Performance of drug classes for Parkinson' s disease in the seven
major markets, 2008 vs. 2018
- Figure: Demographic changes in the general US population, 2005 - 2018
- Figure: Percentage change in the 60 years and older population in the
seven major markets and BRIC countries, 2009 - 2018
- Figure: US Parkinson' s disease-specific sales by class, 2005 - 2018
- Figure: Performance of drug classes for Parkinson' s disease in the US,
2008 vs. 2018
- Figure: Generic incursion on Requip (ropinirole) in the US, Q2 2008 - Q4
2008
- Figure: Mirapex sales volume (IMS Standard Units sold) in the US, Q1 2008
- Q4 2008
- Figure: Japan Parkinson' s disease-specific sales by class, 2005 - 2018
- Figure: Performance of drug classes for Parkinson' s disease in Japan, 2008
vs. 2018
- Figure: Percentage of the population aged over 60 in Japan, the US and
5EU, 2009 - 2018
- Figure: Parkinson' s disease-specific sales by class across the 5EU, 2005 -
2018
- Figure: Performance of drug classes for Parkinson' s disease in the five
major European markets, 2008 vs. 2018
- Figure: AIFA drug innovation evaluation criteria in Italy, 2008
- Figure: French Parkinson' s disease-specific sales by class, 2005 - 2018
- Figure: German Parkinson' s disease-specific sales by class, 2005 - 2018
- Figure: Italian Parkinson' s disease-specific sales by class, 2005 - 2018
- Figure: Spanish Parkinson' s disease-specific sales by class, 2005 - 2018
- Figure: UK Parkinson' s disease-specific sales by class, 2005 - 20
- Figure: Rest of the world versus seven major market sales split in the
Parkinson' s disease market ($m), 2008
- Figure: Global Parkinson' s disease-specific sales ($m), 2005 - 08
- Figure: Parkinson' s disease-specific sales ($m) for key brands in the
seven major pharmaceutical markets, 2005 - 2018
- Figure: Parkinson' s disease patient care pathway, 2009
- Figure: Drivers of brand choice for Parkinson' s disease, 2009
- Figure: Positioning of Mirapex (or pramipexole extended-release) as a
dopamine agonist in Parkinson' s disease treatment
- Figure: Double-blind evaluation of pramipexole extended-release (ER) in
early Parkinson' s disease
- Figure: Double-blind evaluation of maintenance of efficacy of pramipexole
extended-release (ER) in early Parkinson' s disease
- Figure: Overnight switching from immediate- to extended-release
pramipexole in early Parkinson' s disease
- Figure: SWOT analysis for Mirapex (pramipexole), 2009
- Figure: Mirapex and pramipexole extended-release Parkinson' s
disease-specific sales ($m) across the seven major markets, 2005 - 2018
- Figure: Quarterly Parkinson' s disease-specific sales value ($m) for the
Requip (ropinirole) franchise in the US and 5EU, 2008
- Figure: Quarterly Parkinson' s disease-specific sales volume (IMS Standard
Units sold, millions) for the Requip (ropinirole) franchise in the US and 5EU,
2008
- Figure: Company reported and Datamonitor projected total brand sales for
the Requip franchise in the US, Q3 2006 - Q4 2009
- Figure: Positioning of Requip (IR or XL) as a dopamine agonist in
Parkinson' s disease treatment
- Figure: SWOT analysis for the Requip franchise (ropinirole), 2009
- Figure: Requip and Requip XL Parkinson' s disease-specific sales ($m)
across the seven major markets, 2005 - 2018
- Figure: Positioning of Neupro in Parkinson' s disease treatment
- Figure: SWOT analysis for Neupro (rotigotine patch), 2009
- Figure: Neupro Parkinson' s disease-specific sales ($m) across the seven
major markets, 2005 - 2018
- Figure: Azilect mechanism of action in Parkinson' s disease
- Figure: Positioning of Azilect in Parkinson' s disease treatment
- Figure: Quarterly Parkinson' s disease-specific sales volume (million
Standard Units) for Azilect (rasagaline) in the US and 5EU, Q2 2005 - Q4 2008
- Figure: Azilect clinical pharmacology study design
- Figure: SWOT analysis for Azilect (rasagiline), 2009
- Figure: Azilect Parkinson' s disease-specific sales across the seven major
markets ($m), 2005 - 2018
- Figure: Comtan' s mechanism of action in Parkinson' s disease
- Figure: Positioning of Comtan in Parkinson' s disease treatment
- Figure: SWOT analysis for Comtan (entacapone), 2009
- Figure: Comtan Parkinson' s disease-specific sales ($m) across the seven
major markets, 2005 - 2018
- Figure: Stalevo' s mechanism of action in Parkinson' s disease
- Figure: Positioning of Stalevo in Parkinson' s disease treatment
- Figure: Responder rate in the FIRST-STEP Stalevo clinical trial
- Figure: SWOT analysis for Stalevo (levodopa/carbidopa/entacapone), 2009
- Figure: Stalevo Parkinson' s disease-specific sales across the seven major
markets($m), 2005 - 2018
- Figure: Duodopa' s mechanism of action in Parkinson' s disease
- Figure: Positioning of Duodopa (intestinal levodopa/carbidopa) in
Parkinson' s disease treatment
- Figure: SWOT analysis for Duodopa (levodopa/carbidopa), 2009
- Figure: Duodopa Parkinson' s disease-specific sales ($m) seven major
markets, 2005 - 2018
- Figure: Levodopa and decarboxylase inhibitor brands' mechanism of action
in Parkinson' s disease
- Figure: Positioning of levodopa/carbidopa formulations in Parkinson' s
disease treatment
- Figure: Sinemet, Madopar and Parcopa Parkinson' s disease-specific sales
($m) across the seven major markets, 2005 - 2018
- Figure: Safinamide in Parkinson' s disease clinical program, 2009
- Figure: Study design for study 16, add-on to levodopa in mid-to-late stage
patients
- Figure: Positioning of safinamide in Parkinson' s disease treatment
- Figure: Safinamide Parkinson' s disease-specific sales ($m) across the US
and 5EU, 2011 - 18
- Figure: Novartis' s entacapone franchise sales ($m) across the seven major
pharmaceutical markets, 2005 - 2018
- Figure: Percentage of patients adequately controlled at each severity
- Figure: Second-line advanced Parkinson' s disease market, 2005 - 08
- Figure: Second-line advanced Parkinson' s disease market, 2005 - 2018
- Figure: APO-go prefilled multiple dose pen device
- Figure: Crono APO-go pump
- Figure: Duodopa delivery system for Parkinson' s disease
- Figure: Aspirair single unit-dose inhaler
- Figure: Percentage of Parkinson' s disease patients undergoing surgical
procedures in the seven major markets, 2007
|
Related Report
|
View Cart
